CN102413832B - 降低人眼内压的方法 - Google Patents

降低人眼内压的方法 Download PDF

Info

Publication number
CN102413832B
CN102413832B CN201080018539.XA CN201080018539A CN102413832B CN 102413832 B CN102413832 B CN 102413832B CN 201080018539 A CN201080018539 A CN 201080018539A CN 102413832 B CN102413832 B CN 102413832B
Authority
CN
China
Prior art keywords
iop
compound
affected eye
reduced
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080018539.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102413832A (zh
Inventor
施哈·巴曼
鲁道夫·A·鲍姆加特内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rocket Pharmaceuticals Inc
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102413832(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of CN102413832A publication Critical patent/CN102413832A/zh
Application granted granted Critical
Publication of CN102413832B publication Critical patent/CN102413832B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
CN201080018539.XA 2009-05-01 2010-04-30 降低人眼内压的方法 Expired - Fee Related CN102413832B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US61/174,655 2009-05-01
US21999009P 2009-06-24 2009-06-24
US61/219,990 2009-06-24
PCT/US2010/033112 WO2010127210A1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans

Publications (2)

Publication Number Publication Date
CN102413832A CN102413832A (zh) 2012-04-11
CN102413832B true CN102413832B (zh) 2015-11-25

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080018539.XA Expired - Fee Related CN102413832B (zh) 2009-05-01 2010-04-30 降低人眼内压的方法

Country Status (25)

Country Link
US (2) US8470800B2 (enExample)
EP (1) EP2424546B1 (enExample)
JP (1) JP5778663B2 (enExample)
KR (1) KR101757940B1 (enExample)
CN (1) CN102413832B (enExample)
AU (1) AU2010242943B2 (enExample)
BR (1) BRPI1009971A2 (enExample)
CA (1) CA2762064A1 (enExample)
CL (1) CL2011002675A1 (enExample)
DK (1) DK2424546T3 (enExample)
EA (1) EA024042B1 (enExample)
ES (1) ES2554684T3 (enExample)
HR (1) HRP20151200T1 (enExample)
HU (1) HUE028068T2 (enExample)
IL (1) IL216081A (enExample)
MX (1) MX2011011229A (enExample)
MY (1) MY159244A (enExample)
NZ (1) NZ596428A (enExample)
PL (1) PL2424546T3 (enExample)
PT (1) PT2424546E (enExample)
RS (1) RS54378B1 (enExample)
SG (1) SG175346A1 (enExample)
SI (1) SI2424546T1 (enExample)
SM (1) SMT201500295B (enExample)
WO (1) WO2010127210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
KR20120091049A (ko) * 2009-10-26 2012-08-17 이노텍 파마슈티컬스 코포레이션 안과용 제제 및 이의 제조 방법
JP2013516495A (ja) * 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
CN102933220A (zh) * 2010-03-19 2013-02-13 伊诺泰克制药公司 用于降低眼内压的腺苷a1激动剂与碳酸酐酶抑制剂的组合型组合物
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
SMT201700377T1 (it) * 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
KR20170123605A (ko) * 2014-12-03 2017-11-08 이노텍 파마슈티컬스 코포레이션 황반 변성의 예방, 완화 또는 치료 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010085A (zh) * 2004-05-26 2007-08-01 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CN101321460A (zh) * 2005-11-30 2008-12-10 伊诺泰克制药公司 嘌呤衍生物及其用法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01072B (me) 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
KR20120091049A (ko) * 2009-10-26 2012-08-17 이노텍 파마슈티컬스 코포레이션 안과용 제제 및 이의 제조 방법
JP2013516495A (ja) * 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
CN102933220A (zh) * 2010-03-19 2013-02-13 伊诺泰克制药公司 用于降低眼内压的腺苷a1激动剂与碳酸酐酶抑制剂的组合型组合物
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010085A (zh) * 2004-05-26 2007-08-01 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CN101321460A (zh) * 2005-11-30 2008-12-10 伊诺泰克制药公司 嘌呤衍生物及其用法

Also Published As

Publication number Publication date
PT2424546E (pt) 2015-12-23
HK1167599A1 (en) 2012-12-07
EA024042B1 (ru) 2016-08-31
CN102413832A (zh) 2012-04-11
BRPI1009971A2 (pt) 2016-03-15
DK2424546T3 (en) 2015-12-14
SG175346A1 (en) 2011-11-28
MX2011011229A (es) 2011-11-18
IL216081A0 (en) 2012-01-31
JP5778663B2 (ja) 2015-09-16
ES2554684T3 (es) 2015-12-22
EP2424546A4 (en) 2013-01-23
JP2012525437A (ja) 2012-10-22
HUE028068T2 (en) 2016-11-28
CL2011002675A1 (es) 2012-06-01
SMT201500295B (it) 2016-01-08
WO2010127210A1 (en) 2010-11-04
SI2424546T1 (sl) 2016-02-29
US20100279970A1 (en) 2010-11-04
KR101757940B1 (ko) 2017-07-13
AU2010242943B2 (en) 2016-09-29
NZ596428A (en) 2014-03-28
EP2424546B1 (en) 2015-10-28
MY159244A (en) 2016-12-30
AU2010242943A1 (en) 2011-12-01
PL2424546T3 (pl) 2016-04-29
RS54378B1 (sr) 2016-04-28
IL216081A (en) 2015-11-30
EP2424546A1 (en) 2012-03-07
US8470800B2 (en) 2013-06-25
HRP20151200T1 (hr) 2016-01-15
CA2762064A1 (en) 2010-11-04
EA201171339A1 (ru) 2012-05-30
US20130217643A1 (en) 2013-08-22
KR20120017026A (ko) 2012-02-27

Similar Documents

Publication Publication Date Title
AU2010242943B2 (en) Method of reducing intraocular pressure in humans
US9370530B2 (en) Combination, kit and method of reducing intraocular pressure
US20140275128A1 (en) Method of providing ocular neuroprotection
JP2013523738A (ja) アデノシン化合物およびそれらの使用
CN102933593A (zh) 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法
HK1167599B (en) Method of reducing intraocular pressure in humans
HK1171194A (en) Combination, kit and method of reducing intraocular pressure
HK1171194B (en) Combination, kit and method of reducing intraocular pressure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20120411

Assignee: Eno Tech Co. Ltd.

Assignor: Inotek Pharmaceuticals Corporation

Contract record no.: 2017990000148

Denomination of invention: Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof

Granted publication date: 20151125

License type: Common License

Record date: 20170425

EE01 Entry into force of recordation of patent licensing contract
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20180430

CF01 Termination of patent right due to non-payment of annual fee